Tachykinin Receptors (Tachykinin Receptor)

Cell surface proteins that bind tachykinins with high affinity and trigger intracellular changes influencing the behavior of cells. Three classes of tachykinin receptors have been characterized, the NK-1; NK-2; and NK-3; which prefer, respectively, substance P, neurokinin A (substance K, neurokinin alpha, neuromedin L), and neurokinin B (neurokinin beta, neuromedin K).

Also Known As:

Networked: 142 relevant articles (13 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Vink, Robert: 5 articles (10/2014 - 05/2011)
2.	Joos, G F: 5 articles (10/2001 - 04/2000)
3.	Suzuki, Hidenori: 4 articles (10/2011 - 08/2002)
4.	Pauwels, R A: 4 articles (10/2001 - 04/2000)
5.	Turner, Renée J: 3 articles (10/2014 - 06/2011)
6.	Uehara, Takayuki: 2 articles (01/2015 - 05/2013)
7.	Mineta, Hiroyuki: 2 articles (01/2015 - 05/2013)
8.	Kanazawa, Takeharu: 2 articles (01/2015 - 05/2013)
9.	Mochizuki, Daiki: 2 articles (01/2015 - 05/2013)
10.	Imai, Atsushi: 2 articles (01/2015 - 05/2013)

Related Diseases

1.	Asthma (Bronchial Asthma) 11/21/1992 - "Tachykinin receptor antagonists may be useful in the treatment of asthma." 06/01/2007 - "There have also been studies to assess the efficacy of tachykinin receptor antagonists in improving indices of asthma control. " 01/01/2011 - "This review systematically examines randomized controlled trials evaluating the effect of tachykinins receptors antagonism on asthma. " 03/01/1997 - "6. Trials of tachykinin receptor antagonists in human asthma have begun, but it is too early to say what their therapeutic impact will be." 01/01/2011 - "The limited available evidence suggests that tachykinin receptors antagonists may decrease airway responsiveness and improve lung function in patients with asthma. "
2.	Stroke (Strokes) 09/18/2012 - "The aim of the present study was to characterize the effects of a combination of an NK1 tachykinin receptor antagonist with tPA, on BBB permeability and functional outcome following transient ischemic stroke in rats. " 01/01/2013 - "The aim of this review is to examine the role of SP in ischaemic stroke and report on the potential utility of NK1 tachykinin receptor antagonists as therapeutic agents. " 02/01/2001 - "Brain tachykinin receptors are proposed as potential drug targets in stroke." 06/01/2011 - "We conclude that inhibition of SP activity with a NK1 tachykinin receptor antagonist is effective in reducing cerebral oedema, BBB permeability and functional deficits following reversible ischemia and may therefore represent a novel therapeutic approach to the treatment of ischaemic stroke." 09/18/2012 - "We have recently reported on the efficacy of an NK1 tachykinin receptor antagonist in improving outcome following stroke, including reduced blood-brain barrier (BBB) disruption, reduced cerebral edema and improved functional outcome. "
3.	Pain (Aches) 04/01/2013 - "Opioid and tachykinin receptors (TACRs) are closely related in addiction and pain processes. " 08/01/2002 - "Tachykinin receptor antagonists have been also attracting much attention as a novel therapeutic drug for anxiety and depression other than pain. " 01/01/2000 - "Together with the previous findings of the inhibition of hypertensive and tachycardic responses to pain, the present data indicate that tachykinin receptor antagonists can effectively inhibit the generation of an integrated cardiovascular and behavioural response pattern to noxious stimuli." 03/26/1998 - "Effects of tachykinin receptor antagonists on the rat jejunal distension pain response." 07/01/1994 - "The role of tachykinin receptors in both colonic motor disturbances and visceral pain (abdominal contractions as an index of visceral pain) induced by rectal distension were investigated. "
4.	Inflammation 06/01/2001 - "Recent advances in tachykinin receptor pharmacology have allowed a more detailed analysis of this system and preclinical animal studies have indicated a role for the NK1 and NK2 receptors in bronchoconstriction, airway hyperresponsiveness and airway inflammation caused by allergic and nonallergic stimuli. " 03/01/2011 - "It is involved in multiple physiological functions such as inflammation, hematopoietic cells development and vasodilatation via the interaction with tachykinin receptor neurokinin-1 (NK1). " 01/01/2010 - "Investigating the expression levels of genes involved in the regulation of epithelial permeability, bladder contractility, and inflammation, we show that neurokinin (NK)1 and NK2 tachykinin receptors were significantly down-regulated in BPS patients. " 01/01/2008 - "Tachykinin receptors on immune cells are activated during inflammation of the gut. " 09/01/2004 - "Interactions of tachykinin receptor antagonists with lipopolysaccharide-induced airway inflammation in mice."
5.	Chronic Obstructive Pulmonary Disease (COPD) 10/19/2001 - "Compounds that are able to block two or three tachykinin receptors hold promise for the treatment of airways diseases such as asthma and/or chronic obstructive pulmonary disease." 03/08/2006 - "Dual NK1/NK2 or triple NK1/NK2/NK3 tachykinin receptor antagonists offer therapeutic potential in airway diseases such as asthma and chronic obstructive pulmonary disease."

Related Drugs and Biologics

1.	Bradykinin
2.	SR 48968 (saredutant)
3.	Tachykinins
4.	Neurokinin-1 Receptors (Neurokinin 1 Receptor)
5.	Capsaicin (Zostrix)
6.	FK 224
7.	Messenger RNA (mRNA)
8.	Formaldehyde (Formol)
9.	RP 67580
10.	Neurokinin-2 Receptors (Neurokinin 2 Receptor)

Related Therapies and Procedures

1.	Intravitreal Injections
2.	Ligation
3.	Subcutaneous Injections
4.	Drug Therapy (Chemotherapy)